Search Results for “vaccine” – Page 32 – media

Iran PHARMA

Organiser：Iran Pharmaceutical Industry Federation Time：October 2nd to 4th, 2024 address：Mashhad Exhibition and Convention Center, Iran Exhibition hall：Mashad Fair Ground Product range: Pharmaceutical machinery: preparation production equipment, pharmaceutical water equipment, traditional Chinese medicine processing equipment, refrigeration equipment, etc Packaging equipment and materials: aluminum-plastic packaging machine, filling machine, tablet press, labeling machine, inkjet printer, anti-counterfeiting printing and packaging and packaging production line, bar code composite technology equipment, adhesive printing and packaging equipment, plastic packaging products, packaging container forming, filling and sealing machine, cartoning packaging machine, bag packaging machine, multi-function bottled packaging machine, glass packaging products and medicinal packaging materials production equipment, etc Laboratory equipment/analysis and testing: laboratory equipment and devices, laboratory consumables, chemical reagents, biochemical/analytical instruments, biotechnology analysis and testing instruments, pharmaceutical testing equipment, food analysis and testing instruments, pharmaceutical industry analysis instruments, etc Fluid equipment: sanitary pumps, valves, fluid engineering, pipes and pipe fittings, microfiltration, ultrafiltration, etc Clean system: clean air ...
- Source: drugdu
- 102
- June 14, 2024
FDA Approves GSK’s Arexvy to Prevent Respiratory Syncytial Virus in Adults Aged 50-59 with Increased Risk

Don Tracy, Associate Editor Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease. GSK’s Arexvy (RSV Vaccine, Adjuvanted) has been approved by the FDA for an expanded indication to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in adults aged 50-59 years with an increased risk. The approval for this age group was based on encouraging results from a Phase III trial (NCT05590403) that evaluated the immune response and safety of Arexvy in adults aged 50-59, including those with underlying medical conditions. Arexvy was previously approved for adults aged 60 years and older for the same purpose in May 2023. Additionally, the Advisory Committee on Immunization Practices (ACIP) recommended its use through shared clinical decision-making.1 “[This] approval reflects the importance of broadening the benefits of RSV immunization to adults aged 50-59 who are at increased risk. For those ...
- Source: drugdu
- 104
- June 12, 2024
Merck KGaA announces its largest investment in Asia

Merck KGaA Darmstadt Germany announced its largest investment in Asia through a ceremony of its € 300 million Bioprocessing Production Center in Daejeon, South Korea. The new facility will accelerate the biotech and pharmaceutical industry’s development by manufacturing vaccines, cell and gene therapies, and protein-based therapies. Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies. The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel- CEO of the Life Science business, Karen Madden- Chief Technology Officer, Life Science business, Sebastián Arana- Head, Process Solutions, Life Science business, Ivan Donzelot- Head of Integrated Supply Chain Operations. They were joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo, Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.
- Source: drugdu
- 89
- May 31, 2024
Emcure and Gennova to resume mRNA collaboration with HDT

Emcure Pharmaceuticals and its biotech subsidiary, Gennova Biopharmaceuticals have amicably resolved all legal disputes with HDT Bio Corporation. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines, will once again collaborate on the development and commercialisation of mRNA vaccines. The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields. https://www.business-standard.com/companies/news/emcure-gennova-settle-legal-dispute-with-us-based-hdt-bio-sign-agreement-124052300762_1.html
- Source: drugdu
- 95
- May 30, 2024
Emcure and Gennova to resume mRNA collaboration with HDT

Emcure Pharmaceuticals and its biotech subsidiary, Gennova Biopharmaceuticals have amicably resolved all legal disputes with HDT Bio Corporation. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines, will once again collaborate on the development and commercialisation of mRNA vaccines. The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields. https://www.business-standard.com/companies/news/emcure-gennova-settle-legal-dispute-with-us-based-hdt-bio-sign-agreement-124052300762_1.html
- Source: drugdu
- 147
- May 27, 2024
NHS addresses shortage of ethnic organ and blood donors with £600,000 funding

The funding aims to reduce health inequalities in these groups and save more lives The Community Grants Programme led by NHS Blood and Transplant (NHSBT) has dedicated £600,000 to address the shortage of organ and blood donors from black, Asian and mixed ethnic backgrounds. The funding builds on the ongoing commitment by the government and the NHS to address health inequalities for individuals who need life-saving transplants or regular blood transfusions. The Community Grants Programme funds projects led by community, faith or belief organisations to provide greater awareness and support for donations, particularly among black and Asian communities. Furthermore, the scheme aims to inform and recruit more donors of black heritage to treat people with sickle cell disease, the fastest growing blood disorder in the UK, which is more prevalent in people of this heritage. The NHSBT is seeking applications to engage diverse communities across England and Wales and is ...
- Source: drugdu
- 98
- May 23, 2024
CanSinoBio’s Yu Xuefeng was invited to attend the Asia Healthcare Summit Forum

On May 16, the 4th Asia Healthcare Summit (ASGH), jointly organized by the Hong Kong SAR Government and the Hong Kong Trade Development Council, was held at the Hong Kong Convention and Exhibition Centre. Under the theme of “Innovation – Inclusion – Effectiveness”, the forum covered topics such as challenges and opportunities in the global healthcare industry, the latest developments in medical technology and business opportunities in the Asian healthcare industry, aiming to bring together elites in the global healthcare field to explore ways of innovation and development. Dr. Xuefeng Yu, Chairman and CEO of CanSinoBio, was invited to attend the event to discuss the prospects and business opportunities of the Asian healthcare industry with policy makers, healthcare experts, scholars, business leaders and investors from all over the world, and to strengthen the communication and cooperation among global healthcare industry participants. At the conference, Academician Cao Xuetao, Deputy Director of ...
- Source: drugdu
- 82
- May 21, 2024
Liverpool and McMaster University announce £300,000 strategic research partnership

Areas include health research across life stages, from paediatrics to health ageing and resilience The University of Liverpool and McMaster University have announced an institutional strategic partnership, offering £300,000 in seed funding to nine selected projects to support the development of collaborations in key areas of research. The areas of research include health research across life stages, from paediatrics to healthy ageing and resilience, along with social sciences, humanities and research, as well as development in port-related activities. The projects selected were announced by McMaster at a celebratory event with representatives from the University of Liverpool in attendance. The three health research projects selected focus on innovative antibiotic discovery to combat invasive Salmonella in Africa, engineering perfusable vascular organoids for ageing and chronic disease studies and developing pharmacogenetic polygenic risk scores using machine learning methods. David Farrar, president, McMaster, commented: “We’re proud to partner with the University of Liverpool to ...
- Source: drugdu
- 79
- May 21, 2024
New DNA Origami Technique to Advance Disease Diagnosis

DNA origami is a method used to create nanostructures with exceptional precision, utilizing DNA strands as the foundational building blocks. These structures, however, are inherently fragile and prone to disintegration under biological conditions, such as fluctuations in temperature or the presence of certain enzymes in living organisms. To address this vulnerability, researchers have now devised an innovative method to both customize and strengthen DNA origami, offering the potential to advance drug delivery and disease diagnostics. A team of scientists from the universities of Portsmouth (Portsmouth, UK) and Leicester (Leicester, UK) has pioneered a novel approach to reinforce these origami structures, making them both stronger and more adaptable through a process they call triplex-directed photo-cross-linking. This technique involves the strategic addition of new nucleotide sequences to the DNA during the design phase. These sequences are the basic building blocks of DNA and act as attachment points for functional molecules, enhancing the ...
- Source: drugdu
- 90
- May 17, 2024
New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections

Until now, researchers and clinicians have lacked diagnostic tools to easily differentiate between past infections with different flaviviruses—a family of mostly mosquito- and tick-borne viruses that include Zika and dengue. This challenge has hindered clinical-epidemiologic studies, viral diagnostics, and vaccine development. Antibodies for Zika virus, a mosquito-borne virus that spread to the Americas in 2015 and continues to cause sporadic outbreaks, can often be mistaken for dengue virus antibodies in many diagnostic tests. This confusion makes it difficult to determine if a person who tests positive had dengue, Zika, or both. For reproductive-age women, it is particularly crucial to know if they have had Zika and likely have immunity since infection during pregnancy can lead to birth defects. Knowing their immunity status can guide their efforts to avoid mosquito bites in endemic areas during pregnancy. Now, a newly discovered Zika virus-specific synthetic molecule can distinguish Zika-immune patient samples from those ...
- Source: drugdu
- 94
- May 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.